Opus Genetics IRD Stock options excluded as their inclusion would be anti-dilutive (in shares)

Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies

Acco BrandsACCO

8.4M-11.6%

Diversified Energy DEC

2M+46.2%

ValvolineVVV

600K+500%

NFB

Northfield BancorpNFBK

140.2K-87.1%

The Honest CompanyHNST

11.2M+2,827%

Payoneer Global Inc.PAYO

38.4M+44.1%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's stock options excluded as their inclusion would be anti-dilutive (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's stock options excluded as their inclusion would be anti-dilutive (in shares)?: Opus Genetics (IRD) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 34.8M in Q1 2026.